Treatment of Veterans With Advanced NSCLC: Guidance on Current Clinical Strategies

Register Now

Acquire expert insight on the optimal care for your VHA patients with NSCLC in this complimentary, interactive 1-hour live meeting.

Agenda

NSCLC Overview: Clinical, Histologic, and Molecular Assessment and Workup

Case Studies: Evidence-Based Therapy Selection in NSCLC Based on Molecular Profiling

  • Targeted therapy
  • First-line immunotherapy
  • Management of treatment-related adverse events

Case Studies: Evidence-Based Therapy Selection for Biomarker-Negative NSCLC

  • First-line chemotherapy
  • Second-line immunotherapy
  • Management of treatment-related adverse events

Question and Answer Session

Events

Date / Time
Event Details
10/19/2017
12:00 PM

Treatment of Veterans With Advanced NSCLC: Guidance on Current Clinical Strategies

Dallas, TX
VA North Texas Healthcare System - Dallas VA Medical Center Details

Faculty

Program Director
Lyudmila Bazhenova, MD

Clinical Professor of Medicine 
Lung Cancer Unit Leader
Division of Hematology-Oncology
Department of Medicine
University of California, San Diego
San Diego, California

Program Director
Jonathan Dowell, MD

Associate Professor of Internal Medicine
Department of Hematology/Oncology
University of Texas Southwestern Medical Center
Chief, Section of Hematology/Oncology
Dallas VA Medical Center
Dallas, Texas

Faculty
Christina Baik, MD, MPH

Assistant Professor
Thoracic, Head and Neck Medical Oncology
Seattle Cancer Care Alliance
Fred Hutchinson Cancer Research Center
University of Washington
Seattle, Washington

Faculty
Jessica Bauman, MD

Assistant Professor
Department of Hematology-Oncology
Associate Program Director, Hematology-
Oncology Fellowship
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Faculty
Joshua Bauml, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University
of Pennsylvania
Philadelphia, Pennsylvania

Faculty
Alberto Chiappori, MD

Professor
Oncologic Sciences
USF College of Medicine
Senior Member
Thoracic Oncology
Moffitt Cancer Center
Tampa, Florida

Faculty
Millie Das, MD

Clinical Assistant Professor
Division of Oncology
Department of Medicine
Stanford University
Stanford, California
Chief
Oncology Section
Department of Medicine
VA Palo Alto Health Care System
Palo Alto, California

Faculty
Shirish Gadgeel, MD

Professor
Division of Hematology/Oncology
Department of Internal Medicine
University of Michigan
Ann Arbor, Michigan

Faculty
Apar Kishor Ganti, MD, MS, FACP

Staff Physician
VA Nebraska Western Iowa Health Care System
Professor of Medicine
Division of Oncology-Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Faculty
Leora Horn, MD, MSc, FRCPC

Associate Professor of Medicine
Clinical Director, Thoracic Oncology
Research Program
Assistant Vice Chairman for Faculty
Development

Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Faculty
Mark Klein, MD

Assistant Professor of Medicine
Division of Hematology, Oncology, and Transplantation
University of Minnesota
Minneapolis, Minnesota

Faculty
Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Faculty
Sai-Hong Ignatius Ou, MD, PhD

Health Science Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California Irvine School of Medicine
Irvine, California

CME

Goal Statement
The goal of this activity is to improve participants’ competence in treating patients with non-small-cell lung cancer.

Target Audience
This activity is intended for physicians, registered nurses, and other healthcare professionals who care for patients with non-small-cell lung cancer.

Learning Objectives

  • Assess clinical, histologic, and molecular information to individualize the treatment of patients with advanced non-small-cell lung cancer
  • Integrate the latest guidelines and clinical data to the treatment of patients with advanced-stage non-small-cell lung cancer based on tumor histology
  • Apply the latest guidelines and clinical data to the treatment of patients with advanced-stage non-small-cell lung cancer based on molecular markers
  • Manage treatment-related adverse events in patients with advanced non-small-cell lung cancer

Accreditation

Physician Continuing Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.